Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aurobindo Pharma Limited

https://www.aurobindo.com/

Latest From Aurobindo Pharma Limited

Deciphering Molnupiravir’s India Trial Discontinuation In Moderate COVID-19

Two Indian firms want to terminate specific Phase III trials for molnupiravir, the Merck/ Ridgeback Biotherapeutics’ antiviral in the spotlight as a treatment for mild-to-moderate COVID-19. Should much be read into these plans or is it merely an “administrative closure” that is being sought?

Research & Development Coronavirus COVID-19

As Cilta-Cel’s Big Day Approaches, Legend Looks Beyond Myeloma

CEO Ying Huang talked about the biotech’s plans for CAR-T therapies after its J&J-partnered program.

Clinical Trials Regenerative Medicine

Aurobindo’s Arrow Sees Advantages From New French Site

Aurobindo says a new logistics and industrial site opened in France by local subsidiary Laboratoire Arrow will support the firm’s growth plans in the French market.

Strategy Distribution

Aurobindo Files First Biosimilar In Europe With Pegfilgrastim

Aurobindo has submitted its first biosimilar application to the EMA, with the Indian company’s CuraTeQ subsidiary filing its BP14 pegfilgrastim rival to Neulasta.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Acrotech Biopharma, LLC
    • APL
    • Glaxo (India)
    • TL Biopharmaceutical AG.
UsernamePublicRestriction

Register